Indegene Ltd. benchmarking: Performance to industry peers

Financial

	Indegene	Syngene Internation.	Jubilant Pharmova
Operational Metrics
Software Services
Active Clients	63.0 .	n/a	n/a
Financials
5 yr Average ROE	26.35 %	12.33 %	8.05 %
5yr average Equity Multiplier	1.68	1.57	1.96
5yr Average Asset Turnover Ratio	1.21	0.52	0.61
5yr Avg Net Profit Margin	12.84 %	15.3 %	6.45 %
Price to Book	3.7	3.53	2.01
P/E	24.17	47.45	30.62
5yr Avg Cash Conversion Cycle	89.95 Days	-6453.7 Days	-39.98 Days
Inventory Days	0.0	20.52 Days	74.06 Days
Days Receivable	89.95 Days	48.33 Days	45.59 Days
Days Payable	0.0	-264.76 Days	149.89 Days
5yr Average Interest Coverage Ratio	24.33	16.15	3.78
5yr Avg ROCE	34.13 %	13.11 %	8.15 %
5yr Avg Operating Profit Margin	19.32 %	29.04 %	16.76 %
5 yr average Debt to Equity	0.15	0.15	0.55
5yr CAGR Net Profit	22.17 %	4.15 %	0.08 %
5yr Average Return on Assets	15.63 %	7.88 %	4.12 %
Shareholdings
Promoter Holding	0.0	52.68 %	47.68 %
Share Pledged by Promoters	0.0	0.0	5.4 %
Change in Promoter Holding (3 Yrs)	0.0	-12.18 %	-3.0 %
Change in Mutual Fund Holding (3 Yrs)	2.12 %	17.7 %	7.29 %

Business

	Indegene	Syngene Internation.	Jubilant Pharmova
Product Wise Break-Up	Product Wise Break-Up Enterprise Commercial Solutions 58.5 Enterprise Medical Solutions 28.0 Omnichannel Activation 10.0 CDMO 0 Discovery Services 0 Dedicated Centres 0 0 0 Radiopharmaceuticals 0 Allergy therapy products 0 Active pharmaceutical ingredients 0 India Branded pharmaceuticals 0 Nutritional products 0 Specialty intermediates 0 Life science chemicals 0 0 Solid dosage formulations 0 Others 3.5	Product Wise Break-Up 0 Radiopharmaceuticals 0 India Branded pharmaceuticals 0 Life science chemicals 0 Active pharmaceutical ingredients 0 Discovery Services 0 Allergy therapy products 0 Dedicated Centres 0 Nutritional products 0 0 CDMO 0 Solid dosage formulations 0 Enterprise Commercial Solutions 0 Contract Research & Contract Manufacturing (CRAMS) 96.59 Specialty intermediates 0 Omnichannel Activation 0 Enterprise Medical Solutions 0 Others 3.41	Product Wise Break-Up Contract Manufacturing 17.66 Radiopharmaceuticals 46.89 India branded pharmaceuticals 0.7 Life science chemicals 0 Active Pharmaceutical Ingredient (API) 7.91 Discovery Services 0 Anti-allergic 9.75 Dedicated Centres 0 Nutritional products 0 Contract Research and Development Services 7.87 CDMO 0 Solid dosage formulations 8.71 Enterprise Commercial Solutions 0 0 Specialty intermediates 0 Omnichannel Activation 0 Enterprise Medical Solutions 0 Others 0.51
Location Wise Break-Up	Location Wise Break-Up North America 69.6 Europe 27.0 India 0.7 Rest of the World 0 Japan 0 USA 0 China 0 Americas and Europe 0 Others 2.7	Location Wise Break-Up Rest of the World 4.25 Europe 32.05 Japan 0 Americas and Europe 0 USA 61.93 North America 0 India 1.77 China 0	Location Wise Break-Up Rest of the World 5.89 Europe 0 Japan 0 Americas and Europe 91.35 USA 0 North America 0 India 2.76 China 0
Operating Profit Break-Up	Operating Profit Break-Up Enterprise Commercial Solutions 57.84 Enterprise Medical Solutions 34.55 Omnichannel Activation 7.6 Generics 0 CDMO Sterile Injectables 0 Allergy Immunotherapy 0 Radiopharma 0 Proprietary Novel Drugs 0 Contract Research and Development 0 Life Science Ingredients 0 Pharmaceuticals 0 Others 0.01	-	Operating Profit Break-Up Radiopharma 35.32 Life Science Ingredients 0 Pharmaceuticals 0 CDMO Sterile Injectables 26.26 Generics 0 Enterprise Commercial Solutions 0 Allergy Immunotherapy 27.7 Proprietary Novel Drugs 0 Contract Research and Development 10.72 Omnichannel Activation 0 Enterprise Medical Solutions 0
Verticals	Verticals BioPharmaceuticals 92.0 Medical Devices Companies 3.5 Emerging biotech Companies 3.1 Others 1.4	-	-

Indegene Ltd.

Indegene Ltd.

Financial

Business

SIGN UP FOR FREE